go to DCU Home
 
..\Images\People\yeatts.gif
  • Yeatts, Sharon, M.S., Ph.D.
  • Senior Biostatistician
  • Associate Professor of Biostatistics, Department of Public Health Sciences
  • College of Medicine, Medical University of South Carolina
  • Phone:
  • Fax: 843.876.1923
  • Email: yeatts@musc.edu
  • Experience: Phase I-III clinical trials; Experimental design and statistical methods for assessing dose response
  • Research: Design, Conduct, and Analysis of Clinical Trials
  • Projects: Neurological Emergencies (ischemic stroke, intracerebral hemorrhage, traumatic brain injury)
Sharon Yeatts is an Associate Professor of Biostatistics in the Department of Public Health Sciences at the Medical University of South Carolina (MUSC). She received her MS in Statistics from the University of South Carolina (2002) and her PhD in Biostatistics from Virginia Commonwealth University (2006). As a faculty member in the Data Coordination Unit, Dr. Yeatts is involved in the design, conduct, and analysis of multicenter clinical trials in neurological disorders and emergency medicine. Currently, she is the PI of the Data Management Center for the iDEF (Deferoxamine in ICH) and DEFUSE (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) 3 trials. She has completed research grants as the unblinded statistician for the IMS (Interventional Management of Stroke) III and ProTECT (Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment) trials. Dr. Yeatts has interests in early phase trial design, novel trial outcomes, and the analysis of accumulating safety data.

Publications
 
  • Lemmens R, Hamilton SA, Liebeskind DS, Tomsick TA, Demchuk AM, Nogueira RG, Marks MP, Jahan R, Gralla J, Yoo AJ, Yeatts SD, Palesch YY, Saver JL, Pereira VM, Broderick JP, Albers GW, Lansberg MG for the DEFUSE 2, IMS III, STAR and SWIFT trialists.
  • Effect of Endovascular Reperfusion in Relation to Site of Arterial Occlusion.
  • Neurology. 2016; 86(8): 762-70. PMID: 26802090; PMCID: PMC4763803.
  • Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, Jinnah HA.
  • Designing clinical trials for dystonia.
  • Neurotherapeutics. 2014 Jan;11(1):117-27. doi: 10.1007/s13311-013-0221-6.
  • Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators.
  • Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
  • N Engl J Med. 2013 Mar 7;368(10):893-903. doi: 10.1056/NEJMoa1214300. Epub 2013 Feb 7. Erratum in: N Engl J Med. 2013 Mar 28;368(13):1265.

Presentations
 
  • Liebeskind DS, Hill MD, Jovin TG, Menon BK, Nogueira RG, Zaidat OO, Scalzo F, Demchuk AM, Carrozzella J, von Kummer R, Khatri P, Goyal M, Yan B, Foster LD, Yeatts SD, Palesch YY, Broderick JP, Tomsick TA, Yoo AJ, for the IMS III Investigators.
  • Grade 2 or Partial Collaterals in IMS III: Half Full or Half Empty? (Poster)
  • International Stroke Conference, Los Angeles, CA, February 2016.
  • Lansberg M, Bhat N, Broderick JP, Palesch YY, Lavori,PW, Lai TL, Yeatts SD, Albers GW.
  • A Novel Adaptive Trial Design Increases the Power of Endovascular Stroke Studies. (Poster)
  • International Stroke Conference, Los Angeles, CA, February 2016.
  • Albers GA, Lansberg M, Kemp S, Christensen S, Tsai J, Mlynash M, Kim S, Zaharchuck G, Yeatts S, Wintermark M, Bammer R, Palesch Y, Lavori P, Broderick JP, Marks M, on behalf of the DEFUSE 3 Investigators.
  • DEFUSE 3 (Poster)
  • International Stroke Conference, Los Angeles, CA, February 2016.
  • Kim J, Zhoa W, Yeatts SD
  • Implementation of Advanced Randomization Algorithm with Integrated Study Drug Tracking
  • Society for Clinical Trials 36th Annual Meeting, May 2015, Arlington, VA, Oral presentation
  • Vagal A, Menon B, Livorine A, Foster L, Yeatts S, Udgazi E, d'Esterre C, Shu J, Demchuk A, Hill M, Tomsick T, Goyal M.
  • CT Perfusion and Collateral Status in the Interventional Management of Stroke (IMS) III Trial.
  • Presented at the Radiological Society of North America Annual Meeting, Chicago, IL, December 2014. Oral presentation
  • Palesch YY, Yeatts SD, Foster L, Broderick JP for the IMS III Investigators.
  • Endovascular Treatment in the More Severe Stroke Cohort in the Interventional Management of Stroke III Trial May Yield Better Clinical Outcome over 12 Months.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014.
  • Palesch YY, Yeatts SD, Foster L, Broderick JP for the IMS III Investigators.
  • Endovascular Treatment in the More Severe Stroke Cohort in the Interventional Management of Stroke III Trial May Yield Better Clinical Outcome over 12 Months.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014.
  • Khatri P, Yeatts SD, Liebeskind D, Broderick J, Tomsick T for IMS III Trialists.
  • Revascularization Success Whether Measured by Recanalization or Angiographic Reperfusion is Associated with Favorable Clinical Outcome in the IMS III Trial.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014. Poster presentation
  • Menon B, Yeatts S, Qazi E, Triveti A, Mishra S, Nambiar V, Hill MD, Khatri P, Foster L, von Kummer R, Fan L#, Liebeskind D, Puetz V, Tomsick T, Goyal M, Broderick J, Demchuk A.
  • Clot characteristics on baseline imaging predicts recanalization with IV tPA in the IMS III trial.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014. Poster presentation
  • Simpson AN, Simpson KN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP, for the IMS III Investigators.
  • Cost of Inpatient Acute Ischemic Stroke Care in the United States: Findings from the IMS III Trial.
  • Presented at the Academy Health 2014 Annual Research Meeting, San Diego, CA, June 2014.
  • Fan L#, Yeatts SD, Zhao W.
  • Impact of Covariate Misclassification on the Power and Type I Error in Clinical Trials Using Covariate Adaptive Randomization.
  • Presented at the Society for Clinical Trials, Philadelphia, PA, May 2014. Oral presentation.
  • Palesch YY, Martin RL, Yeatts SD, Durkalski VL.
  • Caution! Approaching Interim Analysis.
  • Presented at the Society for Clinical Trials, Philadelphia, PA, May 2014. Oral presentation.
  • Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, Broderick JP, Sandercock P on behalf of the PRISMS and IST-3 Investigators.
  • Effect of IV rtPA in Mild Strokes in the Third International Stroke Trial (IST3): A Post Hoc Analysis.
  • Presented at the American Academy of Neurology Annual Meeting, Philadelphia, PA, April 2014.
  • Foster L, Yeatts S, Tomsick T, Broderick J, Palesch Y.
  • Propensity scores facilitate unbiased comparison of endovascular devices in IMS III.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Poster presentation.
  • Abou-Chebl A, Yeatts S, Yan B, Cockroft K, Goyal M, Khatri P, Meyers P, Spilker J, Sugg R, Wartenberg KE, Tomsick T, Broderick J, Hill MD.
  • Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of IMS III.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Goyal M, Menon B, Fan L#, Demchuk A, Eesa M, Yeatts S, Hill M, Tomsick T, Khatri P, Zaidat O, Jauch E, Jovin T, Broderick on behalf of the IMS III Investigators.
  • Evaluation of Interval Times from Onset to Recanalization in the Patients Undergoing Endovascular Therapy in the IMS III Trial.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Khatri P, Broderick JP, Jauch EC, Levine SR, Romano JG, Saver JL, Yeatts SD, Mu Y, Tayama D on behalf of the PRISMS Investigators.
  • A Phase 3b, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients with Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS).
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Poster presentation.
  • Vagal AS, Eckman M, Broderick JP, Tomsick TA, Yeatts SD, Khatri P.
  • Time to Angiographic Reperfusion: A Decision Analysis.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Poster presentation.
  • Menon BK, Qazi E, Nambiar V, Foster LD, Yeatts SD, Liebeskind D, Jovin T, Hill MD, Goyal, M, Tomsick T, Broderick J, Demchuk AM.
  • Differential Effect of Baseline CTA Collateral Status on Clinical Outcomes in Patients Enrolled in the IMS III Trial.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, Broderick JP, Sandercock P on behalf of the PRISMS and IST-3 Investigators.
  • Effect of IV rtPA in Mild Strokes in the Third International Stroke Trial (IST3): A Post Hoc Analysis.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Poster presentation.
  • Simpson KN, Simpson AN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP.
  • Drivers of Costs Associated with Reperfusion Therapy in Acute Stroke: the IMS III Trial.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Rahme R, Yeatts SD, Abruzzo TA, Jimenez L, Fan L#, Tomsick TA, Ringer AJ, Furlan AJ, Broderick JP, Khatri P.
  • Impact of successful reperfusion on clinical outcome of M2 occlusions: pooled analysis of PROACT-II, IMS-I, and IMS-II.
  • Presented at the XV World Congress of Neurological Surgery of the World Federation of Neurosurgical Societies, Seoul, Korea, September 2013.
  • Yeatts SD, Selim M, Palesch YY.
  • Futility Design Incorporating Concurrent Controls: A Variation on the Phase II Trial Design.
  • Presented at the Society for Clinical Trials, Boston, MA, 2013. Oral presentation.
  • Garofolo KM, Yeatts SD, Ramakrishnan V, Jauch EJ, Johnston KC, Durkalski VL.
  • Responder Analysis Outcomes in the Analysis of Acute Stroke Clinical Trials.
  • Presented at the Society for Clinical Trials, Boston, MA, 2013. Oral presentation.
  • Yeatts SD, Martin RH, Foster LD, Woolson RF, Broderick JP, Palesch YY.
  • The Challenges of Decision-Making Regarding Futility in a Randomized Trial: The IMS III Experience.
  • resented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
    *Among the top 10% of accepted abstracts and invited for presentation at Best of AHA Specialty Conferences at Scientific Sessions 2013 in Dallas, Texas.
  • Khatri P, Yeatts SD, Mazighi M, Broderick JPB, Liebeskind DS, Demchuk AM, Amarenco P, Foster LD, Goyal M, Hill MD, Palesch YY, Jauch EC, Haley EC, Tomsick TA.
  • Time to Angiographic Reperfusion is Highly Associated with Good Clinical Outcome in the Interventional Management of Stroke Phase III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
  • Liebeskind DS, Tomsick TA, Yeatts S, Foster L, Carrozzella J, Jovin TG, Khatri P, Goyal M, Palesch Y, Broderick JPB.
  • Collaterals in the Interventional Management of Stroke (IMS) III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Poster presentation.
  • Nolte J, Gupta P, Davis M, Matheus M, Cianfoni A, Chaudry I, Yeatts S, Rumboldt Z, Turan T.
  • Association Between Low CBV and ICH in Acute Stroke Patients Undergoing Intra-Arterial Therapy.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Poster presentation.
  • Palesch YY, Martin RH, Weng Y, Ramakrishnan V, Yeatts SD
  • Designing a Study for Shift Analysis for Ordinal Data: Application to Acute Stroke Therapy Trials.
  • International Society for Clinical Biostatistics, Munich, Germany, Aug 2013.
go to DPHS

go to MUSC